Morgan Lewis Represents Replimune Group On $150 Million Follow-on Offering
August 12, 2026NEW YORK AND LONDON, August 12, 2026: Morgan Lewis advised biotechnology company Replimune Group Inc. on its registered follow-on offering of 9.7 million shares of common stock and prefunded warrants to purchase 2.7 million shares of common stock. The aggregate gross proceeds to the company were approximately $150 million.
Replimune is a Nasdaq-listed commercial-stage biotechnology company developing oncolytic immunotherapies that target cancer by destroying tumor cells and invoking a systemic immune response. The offering followed the August 6 announcement that the US Food and Drug Administration had granted accelerated approval of the company’s first product, TUDRIQEV, in combination with nivolumab for the treatment of adults with advanced melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen.
The Morgan Lewis capital markets team advising Replimune included partners Tim Corbett, Rahul Patel, and Thurston Hamlette and associates Christina Wlodarczyk and Shabeena Sharak. Partner Jacqueline Berman provided FDA advice and partner Chuck Bogle provided tax advice.